Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00573989 · OUTCOME

Change in Quality of Life: PSS-HN

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
units on a scale
Interval / dispersion
Standard Deviation
Time frame
baseline and 6 months

What was measured

The Performance Status Scale for Head \& Neck Cancer Patients (PSS-HN) is s designed to evaluate performance in areas of functioning most likely affected by head and neck cancer and its treatment, specifically Normalcy of Diet, Eating in Public, and Understandability of Speech. Each subscale is rated from 0 to 100, with higher scores indicating better performance

Analysis population: Data not collected for all participants.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Erlotinib9

Reported measurements

Eating Baseline

Analysis denominator · Participants

GroupSource count
Erlotinib8
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib56.2534.72Not reportedNot reportedNot reported
Eating 6 months

Analysis denominator · Participants

GroupSource count
Erlotinib4
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib43.7523.94Not reportedNot reportedNot reported
Speech Baseline

Analysis denominator · Participants

GroupSource count
Erlotinib8
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib81.2511.57Not reportedNot reportedNot reported
Speech 6 months

Analysis denominator · Participants

GroupSource count
Erlotinib4
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib75.020.41Not reportedNot reportedNot reported
Diet Baseline

Analysis denominator · Participants

GroupSource count
Erlotinib9
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib44.4444.47Not reportedNot reportedNot reported
Diet 6 months

Analysis denominator · Participants

GroupSource count
Erlotinib4
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib25.050.0Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        34.72
        value
        56.25
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    Eating Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.94
        value
        43.75
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Eating 6 months
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.57
        value
        81.25
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    Speech Baseline
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.41
        value
        75.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Speech 6 months
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        44.47
        value
        44.44
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      units
      Participants
    title
    Diet Baseline
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        50.0
        value
        25.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      units
      Participants
    title
    Diet 6 months
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
The Performance Status Scale for Head \& Neck Cancer Patients (PSS-HN) is s designed to evaluate performance in areas of functioning most likely affected by head and neck cancer and its treatment, specifically Normalcy of Diet, Eating in Public, and Understandability of Speech. Each subscale is rated from 0 to 100, with higher scores indicating better performance
dispersion Type
Standard Deviation
groups
  1. description
    Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
    id
    OG000
    title
    Erlotinib
param Type
MEAN
population Description
Data not collected for all participants.
reporting Status
POSTED
time Frame
baseline and 6 months
title
Change in Quality of Life: PSS-HN
type
SECONDARY
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice